UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

May 2017

UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours

Results from a published multicenter study

The results from a German multicenter study were published in the latest issue of Tumor Biology. Principal investigator was  Dr Thorsten Ecke at the Department of Urology, HELIOS Hospital, Bad Saarow.

Urine samples were analyzed with UBC® Rapid POC test and results were determined quantitatively with a reader.

Bladder cancer is one of the most costly cancer diseases, affecting around 2500 persons yearly in Sweden.

The most common method for detection of bladder cancer and for the assessment of recurrence is cystoscopy, a procedure in which an optic fiber is used for examination of the bladder.

The Swedish company IDL Biotech AB has developed a complementary test to cystoscopy – UBC® Rapid, especially useful for detection of high grade bladder cancer.

The test is already clinically documented and is in routine use in Germany.

The combination of UBC® Rapid with an objective POC-reader can enable improved risk stratification.

The new study demonstrated a very high sensitivity (71%) and specificity (94%)for high grade tumors. For patients with cancer in situ (CIS), the sensitivity was even higher (87%). The authors conclude that UBC® Rapid should be added in the diagnostics of high grade tumors and especially for CIS patients.

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia

IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF.

IDL Biotech

Skip this intro